ProShare Advisors
TRVI icon

ProShare Advisors’s Trevi Therapeutics TRVI Stock Holding History

ProShare Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$234K Sell
19,596
-2,673
-12% -$29.9K ﹤0.01% 1478
2025
Q4 		$279K Buy
22,269
+2,947
+15% +$34.1K ﹤0.01% 1501
2025
Q3 		$177K Sell
19,322
-33
-0.2% -$247 ﹤0.01% 1722
2025
Q2 		$106K Sell
19,355
-805
-4% -$5.01K ﹤0.01% 1871
2025
Q1 		$127K Sell
20,160
-525
-3% -$2.5K ﹤0.01% 1786
2024
Q4 		$85.2K Buy
20,685
+9,589
+86% +$30.7K ﹤0.01% 2102
2024
Q3 		$37.1K Buy
+11,096
New +$33K ﹤0.01% 2010

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

ProShare Advisors's TRVI Position: Q1 2026 in Review

ProShare Advisors reduced its Trevi Therapeutics (TRVI) stake by 12% in Q1 2026, selling an estimated $29.9K and leaving 19,596 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #1478.

ProShare Advisors first reported a position in TRVI in Q3 2024 and has held it in 7 quarters since. The position peaked at $279K in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • ProShare Advisors held 19,596 shares of Trevi Therapeutics worth $234K as of Q1 2026.
  • ProShare Advisors sold 2,673 Trevi Therapeutics shares in Q1 2026, an estimated $29.9K.
  • Trevi Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1478 holding.
  • ProShare Advisors first reported a position in Trevi Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • ProShare Advisors's Trevi Therapeutics position peaked at $279K in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.